摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(+/-)-methyl cis-2-(bromomethyl)-1-phenylcyclopropanecarboxylate | 105310-48-3

中文名称
——
中文别名
——
英文名称
(+/-)-methyl cis-2-(bromomethyl)-1-phenylcyclopropanecarboxylate
英文别名
rel-Methyl (1R,2S)-2-(bromomethyl)-1-phenylcyclopropanecarboxylate;methyl (1R,2S)-2-(bromomethyl)-1-phenylcyclopropane-1-carboxylate
(+/-)-methyl cis-2-(bromomethyl)-1-phenylcyclopropanecarboxylate化学式
CAS
105310-48-3
化学式
C12H13BrO2
mdl
——
分子量
269.138
InChiKey
IYFSSGZAXORCOG-PWSUYJOCSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    322.6±25.0 °C(Predicted)
  • 密度:
    1.433±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    2.51
  • 重原子数:
    15.0
  • 可旋转键数:
    3.0
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.42
  • 拓扑面积:
    26.3
  • 氢给体数:
    0.0
  • 氢受体数:
    2.0

SDS

SDS:3bbef7270dff59208e3c7489ce2288be
查看

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    参考文献:
    名称:
    1-芳基-2-(氨基甲基)环丙烷羧酸衍生物。一系列潜在的抗抑郁药。
    摘要:
    合成了一系列的1-芳基-2-(氨基甲基)环丙烷羧酸衍生物,并将其评估为潜在的抗抑郁药。具有Z构型的化合物由1-芳基-2-氧代-3-氧杂双环[3.1.0]己烷合成,具有E构型的化合物由(E)-1-苯基-2-(羟甲基)环丙烷羧酸合成。在动物试验中对化合物进行了评估,旨在揭示其潜在的抗抑郁活性和不良副作用的存在。几种衍生物比丙咪嗪和地昔帕明更具活性。根据其在抗抑郁药理动物实验中的活性及其潜在的无副作用,选择了1-苯基-1-[((二乙基氨基)羰基] -2-(氨基甲基)环丙烷盐酸盐,中alcipranan(INN)。进一步的发展。
    DOI:
    10.1021/jm00385a013
  • 作为产物:
    参考文献:
    名称:
    Synthesis of (+)- and (−)-cis-2-[(1-adamantylamino)-methyl]-1-phenylcyclopropane derivatives as high affinity probes for σ1 and σ2 binding sites
    摘要:
    Selective ligands for either sigma(1) (sigma(1)) or sigma(2) binding sites are potentially useful for gaining a better understanding of the physiological functions of these proteins. Moreover, potent and selective homochiral sigma(1) and sigma(2) binding site ligands represent leads to potential radioligands for tumour imaging with positron emission tomography (PET). On the basis of their structural similarity to previous leads, new (+)- and (-)-cis-2-[(1-adamantylamino)-methyl]-1-phenylcyclopropane derivatives were synthesised and their binding affinities for sigma(1) and sigma(2) binding sites were determined. Each enantiomer showed high affinity for both sigma(1) and sigma(2) binding sites, but only (-)-cis-methyl-2-{[1-adamantyl(methyl)amino]methyl}-1-phenylcyclopropane-carboxylate, (-)-4, showed appreciable selectivity for binding to sigma(1) versus sigma(2) sites. The enantiomers of cis-(2-{[1-adamantyl(methyl)amino]methyl}-1-phenylcyclopropyl)methanol, 6, expressed the highest affinity for sigma(1) and sigma(2) binding sites. Ligands (-)-4, (+)-6 and (-)-6 might be rapidly labelled in their N-methyl groups by methylation of the N-desmethyl analogues with [C-11]iodomethane to provide prospective radioligands for PET. The N-desmethyl analogues, which are also high affinity ligands, were prepared and shown to undergo satisfactory methylation with iodomethane. (C) 2002 Elsevier Science S.A. All rights reserved.
    DOI:
    10.1016/s0014-827x(01)01170-3
点击查看最新优质反应信息

文献信息

  • Synthesis and pharmacological evaluation of potent and enantioselective σ1 and σ2 ligands
    作者:Agostino Marrazzo、Orazio Prezzavento、Lorella Pasquinucci、Franco Vittorio、Giuseppe Ronsisvalle
    DOI:10.1016/s0014-827x(01)01039-4
    日期:2001.4
    In a previous study we found that substitutions of the (+)-cis-N-normetazocine nucleus of (+)-MPCB with 1-adamantanamine provide the compound (+/-)-10 with high affinity and selectivity for sigma receptors. Starting with this result we have synthesized a new series of eight 1-phenyl-2-cyclopropylmethylamines structurally related to (+/-)-10, and binding affinities, with respect to sigma(1), sigma(2), opioid and dopaminergic D-2 receptors, have been reported. All compounds showed a negligible opioid and dopaminergic affinity and high selectivity for sigma receptors. Modifications on the amino moiety and methylcarboxyester group of 10 provide compounds with different sigma(1), and sigma(2) binding affinity and selectivity. Moreover, we have also synthesized the respective enantiomers of componds (+/-)-10 and (+/-)-18 in order to evaluate the enantioselectivity for sigma(1) and sigma(2) receptors. The binding data showed that carboxymethylester on the cyclopropane ring was more critical for enantioselectivity than the hydroxymethylenic group. In fact, the (-)-10 enantionter showed a preference for sigma(1) whereas (+)-10 showed a preference for sigma(2), (C) 2001 Elsevier Science S.A. All rights reserved.
  • Substituted 1-phenyl-2-cyclopropylmethylamines with high affinity and selectivity for sigma sites
    作者:Giuseppe Ronsisvalle、Agostino Marrazzo、Orazio Prezzavento、Lorella Pasquinucci、Barbara Falcucci、Rosanna Di Toro、Santi Spampinato
    DOI:10.1016/s0968-0896(00)00072-9
    日期:2000.6
    A series of 1-phenyl-2-cyclopropylmethylamines structurally related to (+)- and (-)-MPCB were synthesized and their binding affinities for or, oz, opioid and dopamine (D-2) receptors were evaluated. Substitution of the cis-N-normetazocine with different aminic moieties provided compounds with high affinity and selectivity for sigma binding sites with respect to opioid and dopamine (D2) receptors. The observed increase in sigma(2) affinity as compared to the parent(+)-MPCB, supports the idea that the particular stereochemistry of (+)-cis-N-normetazocine affects sigma(1) selectivity but does not affect ol affinity. The (+/-)-cis isomers of methyl 2-[(1-adamantylamino)methyl]-1-phenylcyclopropane-1-carboxylate (18) displayed a higher affinity and selectivity for the ol and sigma(2) receptor subtypes compared to the (+/-)-trans 19. interestingly, the enantiomer (-)-cis 18 displayed a preference for ol receptor subtype whereas the (+)-cis 18 did for sigma(2). These results prompt us to synthesize compounds with modification of nitrogen and carboxyl groups. The compounds obtained showed high affinities and selectivity for sigma sites. Moreover, modifications of carboxyl groups provided compounds with the highest affinities in the series. In particular, compound 25 with reverse-type ester showed a K-i of 0.6 and 4.05 nM for sigma(1) and sigma(2) binding sites, respectively. (C) 2000 Elsevier Science Ltd. All rights reserved.
  • Novel Potent and Selective σ Ligands: Evaluation of Their Agonist and Antagonist Properties
    作者:Agostino Marrazzo、Enrique J. Cobos、Carmela Parenti、Giuseppina Aricò、Giuseppina Marrazzo、Simone Ronsisvalle、Lorella Pasquinucci、Orazio Prezzavento、Nicola A. Colabufo、Marialessandra Contino、Luis G. González、Giovanna M. Scoto、Giuseppe Ronsisvalle
    DOI:10.1021/jm200144j
    日期:2011.5.26
    Novel enantiomers and diastereoisomers structurally related to sigma ligand (+)-MR200 were synthesized to improve sigma(1)/sigma(2) subtype selectivity. The selective sigma(1) ligand (-)-8 showed an antagonist profile determined by phenytoin differential modulation of binding affinity in vitro, confirmed in vivo by an increase of kappa opioid analgesia. The sigma(2) ligand (-)-9 displayed agonist properties in an in vitro isolated organ bath assay and antiproliferative effects on LNCaP and PC3 prostate cancer cell lines.
  • A De Novo Designed Inhibitor ofD-Ala-D-Ala Ligase fromE. coli
    作者:Gilbert E. Besong、Julieanne M. Bostock、Will Stubbings、Ian Chopra、David I. Roper、Adrian J. Lloyd、Colin W. G. Fishwick、A. Peter Johnson
    DOI:10.1002/anie.200501662
    日期:2005.10.7
  • BONNAUD B.; COUSSE H.; MOUZIN G.; BRILEY M.; STENGER A.; FAURAN F.; COUZI+, J. MED. CHEM., 30,(1987) N 2, 318-325
    作者:BONNAUD B.、 COUSSE H.、 MOUZIN G.、 BRILEY M.、 STENGER A.、 FAURAN F.、 COUZI+
    DOI:——
    日期:——
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S,S)-邻甲苯基-DIPAMP (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(-)-4,12-双(二苯基膦基)[2.2]对环芳烷(1,5环辛二烯)铑(I)四氟硼酸盐 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[(4-叔丁基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[(3-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-4,7-双(3,5-二-叔丁基苯基)膦基-7“-[(吡啶-2-基甲基)氨基]-2,2”,3,3'-四氢1,1'-螺二茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (R)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4S,4''S)-2,2''-亚环戊基双[4,5-二氢-4-(苯甲基)恶唑] (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (3aR,6aS)-5-氧代六氢环戊基[c]吡咯-2(1H)-羧酸酯 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[((1S,2S)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1S,2S,3R,5R)-2-(苄氧基)甲基-6-氧杂双环[3.1.0]己-3-醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (1-(2,6-二氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙蒿油 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫-d6 龙胆紫